Back

Effect of alirocumab on incidence of atrial fibrillation after acute coronary syndromes: insights from ODYSSEY OUTCOMES

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Atrial Fibrillation ePosters Epidemiology, Prognosis, Outcome ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Renato Lopes

Duke University Medical Center, Durham (United States of America)

172 More presentations in this session

Presentation thumbnail
Atrial fibrillation with or without structural abnormalities. Analysis from a nationwide database.
Doctor V. Mertz (FR)
Abstract Slides
Presentation thumbnail
Epicardial adipose tissue and atrial fibrillation: guilty as charged or guilty by association?
Doctor J. Sousa (Funchal, PT)
Abstract Slides
Presentation thumbnail
Timing and degree of left atrial stunning and reverse functional remodeling following electrical cardioversion in patients with recent onset atrial fibrillation
Doctor P. Arvanitis (Uppsala, SE)
Abstract Slides
Presentation thumbnail
Irregular beat-to-beat hemodynamic properties determine left ventricular function during atrial fibrillation
Doctor A. Lyon (Maastricht, NL)
Abstract Slides
Presentation thumbnail
Genetic susceptibility, elevated blood pressure and risk of atrial fibrillation
Mr M. Nazarzadeh (Oxford, GB)
Abstract Slides

Access the full session

Session thumbnail
Atrial Fibrillation ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET
You may be interested in
thumbnail
Congress Presentation
PCSK9 inhibitors and incidence of arrhythmias in clinical practice: a phase IV multicentric study
18 April 2023
thumbnail
Congress Presentation
Heart failure in patients with and without new-onset atrial fibrillation in the context of acute coronary syndrome
23 May 2023
thumbnail
Congress Presentation
Cost-effectiveness of oral anticoagulant therapy in patients with device-detected atrial fibrillation
12 April 2026
thumbnail
Congress Presentation
Association of lipoprotein(a) levels with risk of serious bleeding : findings from the ODYSSEY OUTCOMES trial
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources